Prescription drug · ANDA
acetaZOLAMIDE NDC 70710-1239
Acetazolamide 250 mg/1 · Tablet · Oral · Zydus Pharmaceuticals (USA) Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70710-1239-1 | 70710123901 | 100 TABLET in 1 BOTTLE (70710-1239-1)Marketed from Aug 4, 2023 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- acetaZOLAMIDE
- Generic name (nonproprietary)
- acetazolamide
- Active ingredients
- Acetazolamide — 250 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211069
- Marketing start
- Listing expires
- Other FDA classes
- Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
- Identifiers
- Product ID 70710-1239_b8ec300c-c64c-4a65-a101-66644f64f9f7SPL ID b8ec300c-c64c-4a65-a101-66644f64f9f7SPL set ID 85e4d8f6-1e82-4068-a768-752287d4ccf2RxCUI 197303, 197304UNII O3FX965V0IUPC 0370710123819, 0370710123918
- Pharmacologic class
- Carbonic Anhydrase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470710123901followed by a unit qualifier and the quantityPackage 70710-1239-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 211069
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| acetaZOLAMIDE | Acetazolamide 125 mg/1 | TabletOral | NuCare Pharmaceuticals,Inc. | 68071-3632 |
| acetaZOLAMIDE | Acetazolamide 125 mg/1 | TabletOral | Viona Pharmaceuticals Inc | 72578-149 |
| acetaZOLAMIDE | Acetazolamide 250 mg/1 | TabletOral | Viona Pharmaceuticals Inc | 72578-150 |
| acetaZOLAMIDE | Acetazolamide 125 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 70710-1238 |
| acetaZOLAMIDE | Acetazolamide 125 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1827 |
| acetaZOLAMIDE | Acetazolamide 250 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1828 |
| acetaZOLAMIDE | Acetazolamide 250 mg/1 | TabletOral | A-S Medication Solutions | 50090-7536 |